MarginsXMarginsX
Home › Markets › Health Care › INBX

Inhibrx Biosciences Inc. (INBX)

INBX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$77.66
-6.77% on the day
Market cap
$1.1B
Small cap
Revenue · 2025
$1.3M
+550.0% on 2024
Net income · 2025
-$140.1M
-10773.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/0002007919-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerINBX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0002007919
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.3M
Net income-$140.1M
Operating income-$135.0M
Net margin-10773.5%
Operating margin-10386.5%
Revenue growth+550.0%
Cash$124.2M
Total assets$146.5M
P/E (computed)Net income was not positive
P/S (computed)879.2×

Warning signs

Cash runway
12.1 months
$133.3M cash at June 30, 2026
Share count, 1 year
+1.5%
2025-11-07 to 2026-11-06
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
-$6.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-13
Cash and burn$133.3M cash; operating cash flow -$33.0M a quarter.Report 2026-06-30
Shares outstanding14,769,076 (2026-11-06); 14,543,738 a year earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., San Diego, California, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5.5M, sold $11.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$36.6M-$29.9M$133.3M$176.3MNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$33.4M-$38.0M$161.7M$175.0MNeeds four quarters10-Q 2026-08-13
Q4 2025
2025-12-31
$0-$32.8M-$30.1M$124.2M$100.6M$1.3M10-K 2026-03-19
Q3 2025
2025-09-30
$0-$35.3M-$33.8M$153.1M$99.9M$1.4M10-Q 2025-11-14
Q2 2025
2025-06-30
$1.3M-$28.7M-$30.0M$186.6M$99.3M$1.4M10-Q 2026-08-13
Q1 2025
2025-03-31
$0-$43.3M-$35.9M$216.5M$98.7M$200K10-Q 2025-05-14
Q4 2024
2024-12-31
$100K-$47.9M-$43.7M$152.6M$0$200K10-K 2026-03-19
Q3 2024
2024-09-30
$0-$43.9M-$30.3M$196.3M$0$1.7M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-13
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 162 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.4%
1 month-4.3%
3 months-14.1%
Year to date+5.4%
1 year+11.6%
From 52-week high-41.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
VORVor Biopharma Inc.$18.97-2.32%$1.2B
TSHATaysha Gene Therapies Inc.$4.06-0.98%$1.3B
NVAXNovavax Inc.$8.06-5.45%$1.3B
ODTXOdyssey Therapeutics Inc.$19.36+1.15%$930.6M
IMTXImmatics N.V.$6.17-3.44%$923.2M
LYCALycia Therapeutics Inc.$28.61-8.30%$1.5B
IMCRImmunocore Holdings plc$28.88-3.54%$1.5B
MGTXMeiraGTx Holdings plc$8.74-4.79%$854.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier